April 26, 2024
Daiichi Sankyo President and COO Hiroyuki Okuzawa Daiichi Sankyo said on April 25 that its revenue jumped 25% over the previous year in FY2023 ended March 2024, spurred by growth of its mainstay cancer drug and anticoagulant. On the back...read more